June 04, 2025

Chemo Killed Her. A Test Might've Saved Her.

A fatal enzyme deficiency turned a common chemo drug toxic. With testing available—but rarely used—are clinicians missing a lifesaving step?

KFF Health News

June 02, 2025

Kids, Interrupted: America’s Youngest Caregivers

Millions of children are caring for sick or disabled adults at home — a growing crisis fueled by shrinking Medicaid funds and fading support systems.

KFF Health News

May 30, 2025

Paging Dr. Canada: U.S. Exodus

Amid Trump’s return, more American doctors are fleeing to Canada, citing political fear, violence, and a collapsing health care climate.

KFF Health News

May 23, 2025

Together, We’re Building a Better Future for People With Cancer and for Our Profession

For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st ...

The ASCO Post

May 20, 2025

Creamy, Dreamy, and Possibly Dangerous

Emulsifiers keep foods creamy—but at what cost?

KFF Health News

May 09, 2025

Sweetie, Stop: The Harm of Elderspeak

Explore how well-meaning but condescending language like “sweetie” and “dearie” can undermine the dignity of older adults.

KFF Health News

July 10, 2023

Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD

Dr. Pamela L. Kunz and Dr. Corrie Marijnen discuss the groundbreaking PROSPECT trial, highlighting the safe omission of radiation in many patients with advanced rectal cancer, improving quality of life and reducing side effects.

The ASCO Post

March 27, 2024

Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions

Discover how a 62-year-old woman's paradoxical reaction during paclitaxel chemotherapy led to a substitution of intravenous diphenhydramine with intravenous cetirizine, highlighting the complexities of managing infusion-related reactions.

JADPRO

November 22, 2024

FDA Official Expects Tightened Vaccine Review

"I don't necessarily view that as a bad thing."

Reuters